ProCE Banner Activity

Don’t Abandon Hope! Monoclonal Antibodies for Prophylaxis or Treatment of COVID-19 in Patients With Immune Compromise

Clinical Thought

Use of monoclonal antibodies is no longer recommended by many COVID-19 guidelines―but do data from ECCMID 2023 suggest they might have a role for prophylaxis or treatment of acute COVID-19 in select patients in Europe?

Released: May 10, 2023

Share

Faculty

Cristina Mussini

Cristina Mussini, MD

Full Professor of Infectious Diseases
Chief of the Clinic of Infectious Diseases, University Hospital of Modena
University of Modena and Reggio Emilia
Modena, Italy

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Provided by educational grants from Gilead Sciences, Inc., Novavax, and Shionogi Inc.

Gilead Sciences, Inc.

Novavax

Faculty Disclosure

Primary Author

Cristina Mussini, MD

Full Professor of Infectious Diseases
Chief of the Clinic of Infectious Diseases, University Hospital of Modena
University of Modena and Reggio Emilia
Modena, Italy

Cristina Mussini, MD: consultant/advisor/speaker: AbbVie, Angelini, Gilead Sciences, GlaxoSmithKline, Janssen, MSD, Pfizer, Roche, ViiV Healthcare; researcher: Gilead Sciences, Janssen, MSD, ViiV Healthcare.